CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
CA2259123C
(en)
*
|
1996-07-01 |
2003-10-21 |
Jim A. Wright |
Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
|
US6593305B1
(en)
*
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
DE69823813T2
(de)
|
1997-03-19 |
2005-06-30 |
Genesense Technologies, Inc., Toronto |
Malignitätsunterdrückung unter verwendung von ribonukleotidreduktase r1
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
EP1584681A3
(en)
*
|
1997-07-10 |
2005-11-09 |
GeneSense Technologies Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
US6610539B1
(en)
*
|
1997-07-10 |
2003-08-26 |
Genesense Technologies, Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
CZ295108B6
(cs)
*
|
1998-03-20 |
2005-05-18 |
Benitec Australia Ltd |
Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
EP2314700A1
(en)
*
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
US6642033B1
(en)
|
1999-07-20 |
2003-11-04 |
V.I. Technologies, Inc. |
Nucleic acids for detecting parvovirus and methods of using same
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
CN1301816A
(zh)
*
|
1999-12-27 |
2001-07-04 |
上海博德基因开发有限公司 |
一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
|
GB2377221B
(en)
*
|
2000-03-17 |
2004-08-18 |
Benitec Australia Ltd |
Genetic silencing
|
US20020132257A1
(en)
*
|
2001-01-31 |
2002-09-19 |
Tony Giordano |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
DE10131148A1
(de)
*
|
2001-06-28 |
2003-01-16 |
I P L Internat Pharmaceutics L |
Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
|
JP2006518344A
(ja)
*
|
2003-02-10 |
2006-08-10 |
ジェネセンス テクノロジーズ インク |
リボヌクレオチド還元酵素r2を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
|
WO2004083432A1
(en)
*
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
US20070274947A1
(en)
*
|
2003-05-21 |
2007-11-29 |
Young Aiping H |
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
|
WO2004106518A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
KR20060116825A
(ko)
|
2003-10-23 |
2006-11-15 |
일루미겐 바이오사이언시스, 인코포레이티드 |
바이러스 감염에 대한 저항성과 관련된 유전자인oas1에서의 돌연변이의 검출
|
US20080311126A1
(en)
*
|
2004-01-12 |
2008-12-18 |
Genesense Technologies, Inc |
Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
|
US8029815B2
(en)
*
|
2004-04-28 |
2011-10-04 |
Elford Howard L |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
JP5697297B2
(ja)
*
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロnasおよびその使用
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US20080255065A1
(en)
*
|
2004-08-18 |
2008-10-16 |
Genesense Technologies, Inc. |
Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
AU2006230436B2
(en)
*
|
2005-03-31 |
2011-11-24 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
EP2030615A3
(en)
*
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
|
WO2010027279A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
EP2727996A1
(en)
|
2008-11-06 |
2014-05-07 |
The Johns-Hopkins University |
Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
EP2630240A1
(en)
*
|
2010-10-18 |
2013-08-28 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of rrm2 genes
|
CN103476777B
(zh)
|
2011-01-31 |
2015-05-27 |
诺瓦提斯公司 |
新杂环衍生物
|
PL2771342T3
(pl)
|
2011-10-28 |
2016-11-30 |
|
Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
|
RU2630975C2
(ru)
|
2012-05-16 |
2017-09-15 |
Новартис Аг |
Режим дозирования pi-3 киназы
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|